By Pedro Romero, Chief Medical Officer, Novigenix. Two recent original research papers published in the March edition of the New England Journal of Medicine highlight the momentum in screening for colorectal carcinoma (CRC) and high-risk colorectal adenomas. These developments mark a significant milestone in the fight against CRC and signal additional momentum for Novigenix’
04.04.2024, Geneva - In a significant step forward for personalized cancer care, Novigenix, a pioneer in AI healthcare solutions, has been selected as a key partner by the IMMUcan consortium for the development of RNA sequencing biomarkers and to advance the understanding of the immune system's response to checkpoint inhibitors in cancer patients. IMMUcan
Geneva, January 16, 2024 - With cancer projected to escalate to 29 million cases by 2040[1], Novigenix, a pioneer in AI healthcare solutions, is rewriting the rules of cancer care. Their newest innovation, LITOSeek™, is primed to reshape drug development, offering a transformative leap forward. Personalized Cancer Treatment: Breaking Barriers Every cancer is as
LAUSANNE, SWITZERLAND – Novigenix, a leading Swiss biotech that develops and commercializes Immuno-Transcriptomic precision oncology solutions, recently announced the appointment of Dr Pedro Romero, MD, PhD as its Chief Medical & Scientific Officer. Dr. Romero has previously served as Director of Medical & Scientific Affairs and on the Medical Advisory Board of Novigenix. In